NCT05794906 2026-03-17
ARASTEP
Bayer
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT06120491 2026-01-21
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT06592924 2026-01-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT04464226 2025-11-06
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Recruiting
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT06276465 2024-12-20
PEACE8
UNICANCER
Phase 3 Recruiting
NCT06496581 2024-12-20
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
Phase 3 Recruiting
NCT04916613 2024-09-26
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
UNICANCER
Phase 3 Recruiting
NCT05116475 2024-03-12
ALADDIN
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Recruiting
NCT05771896 2023-09-14
CARE
GenesisCare USA
Phase 3 Withdrawn
NCT04136353 2023-07-28
DASL-HiCaP
University of Sydney
Phase 3 Active not recruiting
NCT02200614 2022-06-28
ARAMIS
Bayer
Phase 3 Completed